Pierre Socha

Principal

Pierre joined Amadeus Capital Partners in 2012. Pierre has a current investment focus on digital health, medical technology, AI and machine learning and cybersecurity. He is a non-executive director on the boards of Inotec, Repositive, Doctify, Congenica and oversees Amadeus’s investments in PhoreMost, Organox and Antidote (formerly TrialReach).

Pierre brings operational experience to these investments, having managed the growth of several life science businesses in Asia and Europe. During a decade at biotech company Avesthagen, he guided the group’s strategy and European activities, contributing to acquisitions, joint ventures and exits.

Pierre started his career as an auditor with KPMG in France and subsequently worked as a financial engineer at Natixis and as a research fellow in health and urban microeconomics.

Pierre is French and holds an MSc in Environmental Economics (Hons.-SciencesEco) from Université de Provence, France and a BSc in Finance & Econometrics (Math Spe.-SciencesEco) from Université Louis Pasteur, France. He has attended executive programs at Harvard, MIT and Stanford.

Pierre speaks French and English and understands German.

Pierre is the Amadeus contact for

More from Pierre